Tools

ARKG

ARK Genomic Revolution ETF · BATS

  • Category Equity
  • Expense Ratio 0.75%
  • Listing Date Oct 31, 2014
  • Volume 3,647,730.0
  • Market Cap (AUM) $1,231.64M

Performance

+3.93%

1W

+6.66%

1M

+5.85%

3M

-0.15%

6M

-19.45%

YTD

-7.62%

1Y

Top Holdings

  • Name
    Symbol
    %Assets
  • Twist Bioscience Corp.TWST9.71%
  • CRISPR Therapeutics AGCRSP7.94%
  • Recursion Pharmaceuticals, Inc. Class ARXRX6.26%
  • CareDx, Inc.CDNA5.99%
  • Intellia Therapeutics, Inc.NTLA4.65%
  • Ionis Pharmaceuticals, Inc.IONS4.18%
  • Arcturus Therapeutics Holdings, Inc.ARCT3.78%
  • Nurix Therapeutics, Inc.NRIX3.72%
  • Beam Therapeutics, Inc.BEAM3.62%
  • Moderna, Inc.MRNA3.57%

Technical Analysis of ARKG 2024-12-06

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should ...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.